Does the media favor LQDA or PBH?

In the previous week, Prestige Consumer Healthcare had 13 more articles in the media than Liquidia. MarketBeat recorded 20 mentions for Prestige Consumer Healthcare and 7 mentions for Liquidia. Prestige Consumer Healthcare's average media sentiment score of 1.38 beat Liquidia's score of 0.59 indicating that Prestige Consumer Healthcare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prestige Consumer Healthcare 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LNTH or PBH?

In the previous week, Prestige Consumer Healthcare had 12 more articles in the media than Lantheus. MarketBeat recorded 20 mentions for Prestige Consumer Healthcare and 8 mentions for Lantheus. Lantheus' average media sentiment score of 1.52 beat Prestige Consumer Healthcare's score of 1.38 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive Prestige Consumer Healthcare 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BLTE or PBH?

In the previous week, Prestige Consumer Healthcare had 18 more articles in the media than Belite Bio. MarketBeat recorded 20 mentions for Prestige Consumer Healthcare and 2 mentions for Belite Bio. Prestige Consumer Healthcare's average media sentiment score of 1.38 beat Belite Bio's score of 0.62 indicating that Prestige Consumer Healthcare is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prestige Consumer Healthcare 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Prestige Consumer Healthcare (PBH) Competitors

$52.48 +1.27 (+2.48%)

As of 08/28/2026 03:58 PM Eastern

Compare

PBH vs. CRNX, LQDA, LNTH, BLTE, and DFTX

Should you buy Prestige Consumer Healthcare stock or one of its competitors? Prestige Consumer Healthcare's main competitors and comparable companies include Crinetics Pharmaceuticals (CRNX), Liquidia (LQDA), Lantheus (LNTH), Belite Bio (BLTE), and Definium Therapeutics (DFTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Prestige Consumer Healthcare compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

Crinetics Pharmaceuticals has a beta of 0.12, meaning that its stock price is 88% less volatile than the broader market. Comparatively, Prestige Consumer Healthcare has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

Prestige Consumer Healthcare has a net margin of 15.57% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Prestige Consumer Healthcare's return on equity of 11.39% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%
Prestige Consumer Healthcare	15.57%	11.39%	5.66%

Crinetics Pharmaceuticals currently has a consensus target price of $81.00, suggesting a potential downside of 4.53%. Prestige Consumer Healthcare has a consensus target price of $70.75, suggesting a potential upside of 34.81%. Given Prestige Consumer Healthcare's higher possible upside, analysts clearly believe Prestige Consumer Healthcare is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24
Prestige Consumer Healthcare	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 1.5% of Prestige Consumer Healthcare shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Prestige Consumer Healthcare had 10 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 20 mentions for Prestige Consumer Healthcare and 10 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.50 beat Prestige Consumer Healthcare's score of 1.38 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prestige Consumer Healthcare	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prestige Consumer Healthcare has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	1,168.70	-$465.32M	-$5.04	N/A
Prestige Consumer Healthcare	$1.09B	2.28	$190.30M	$3.57	14.70

Summary

Prestige Consumer Healthcare beats Crinetics Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Prestige Consumer Healthcare compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Liquidia has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, Prestige Consumer Healthcare has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

In the previous week, Prestige Consumer Healthcare had 13 more articles in the media than Liquidia. MarketBeat recorded 20 mentions for Prestige Consumer Healthcare and 7 mentions for Liquidia. Prestige Consumer Healthcare's average media sentiment score of 1.38 beat Liquidia's score of 0.59 indicating that Prestige Consumer Healthcare is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prestige Consumer Healthcare	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

64.5% of Liquidia shares are held by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 25.6% of Liquidia shares are held by company insiders. Comparatively, 1.5% of Prestige Consumer Healthcare shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Prestige Consumer Healthcare has higher revenue and earnings than Liquidia. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	38.27	-$68.92M	$1.37	49.41
Prestige Consumer Healthcare	$1.09B	2.28	$190.30M	$3.57	14.70

Liquidia has a net margin of 30.74% compared to Prestige Consumer Healthcare's net margin of 15.57%. Liquidia's return on equity of 149.65% beat Prestige Consumer Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Prestige Consumer Healthcare	15.57%	11.39%	5.66%

Liquidia currently has a consensus target price of $98.08, suggesting a potential upside of 44.90%. Prestige Consumer Healthcare has a consensus target price of $70.75, suggesting a potential upside of 34.81%. Given Liquidia's stronger consensus rating and higher possible upside, analysts clearly believe Liquidia is more favorable than Prestige Consumer Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
Prestige Consumer Healthcare	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

Summary

Liquidia beats Prestige Consumer Healthcare on 11 of the 17 factors compared between the two stocks.

How does Prestige Consumer Healthcare compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

Lantheus has higher revenue and earnings than Prestige Consumer Healthcare. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.34
Prestige Consumer Healthcare	$1.09B	2.28	$190.30M	$3.57	14.70

Lantheus presently has a consensus price target of $108.11, indicating a potential upside of 7.29%. Prestige Consumer Healthcare has a consensus price target of $70.75, indicating a potential upside of 34.81%. Given Prestige Consumer Healthcare's higher possible upside, analysts clearly believe Prestige Consumer Healthcare is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
Prestige Consumer Healthcare	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

Lantheus has a net margin of 17.69% compared to Prestige Consumer Healthcare's net margin of 15.57%. Lantheus' return on equity of 28.10% beat Prestige Consumer Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Prestige Consumer Healthcare	15.57%	11.39%	5.66%

99.1% of Lantheus shares are held by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 1.5% of Prestige Consumer Healthcare shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Lantheus has a beta of -0.03, indicating that its share price is 103% less volatile than the broader market. Comparatively, Prestige Consumer Healthcare has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

In the previous week, Prestige Consumer Healthcare had 12 more articles in the media than Lantheus. MarketBeat recorded 20 mentions for Prestige Consumer Healthcare and 8 mentions for Lantheus. Lantheus' average media sentiment score of 1.52 beat Prestige Consumer Healthcare's score of 1.38 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Prestige Consumer Healthcare	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lantheus beats Prestige Consumer Healthcare on 12 of the 16 factors compared between the two stocks.

How does Prestige Consumer Healthcare compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

Prestige Consumer Healthcare has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Prestige Consumer Healthcare	$1.09B	2.28	$190.30M	$3.57	14.70

Belite Bio has a beta of -1.22, suggesting that its share price is 222% less volatile than the broader market. Comparatively, Prestige Consumer Healthcare has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market.

In the previous week, Prestige Consumer Healthcare had 18 more articles in the media than Belite Bio. MarketBeat recorded 20 mentions for Prestige Consumer Healthcare and 2 mentions for Belite Bio. Prestige Consumer Healthcare's average media sentiment score of 1.38 beat Belite Bio's score of 0.62 indicating that Prestige Consumer Healthcare is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prestige Consumer Healthcare	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Belite Bio presently has a consensus target price of $205.80, indicating a potential upside of 35.64%. Prestige Consumer Healthcare has a consensus target price of $70.75, indicating a potential upside of 34.81%. Given Belite Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Belite Bio is more favorable than Prestige Consumer Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Prestige Consumer Healthcare	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 1.5% of Prestige Consumer Healthcare shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Prestige Consumer Healthcare has a net margin of 15.57% compared to Belite Bio's net margin of 0.00%. Prestige Consumer Healthcare's return on equity of 11.39% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Prestige Consumer Healthcare	15.57%	11.39%	5.66%

Summary

Prestige Consumer Healthcare beats Belite Bio on 11 of the 15 factors compared between the two stocks.

How does Prestige Consumer Healthcare compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

In the previous week, Prestige Consumer Healthcare had 15 more articles in the media than Definium Therapeutics. MarketBeat recorded 20 mentions for Prestige Consumer Healthcare and 5 mentions for Definium Therapeutics. Prestige Consumer Healthcare's average media sentiment score of 1.38 beat Definium Therapeutics' score of 0.76 indicating that Prestige Consumer Healthcare is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prestige Consumer Healthcare	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Definium Therapeutics presently has a consensus target price of $63.00, indicating a potential upside of 53.73%. Prestige Consumer Healthcare has a consensus target price of $70.75, indicating a potential upside of 34.81%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Definium Therapeutics is more favorable than Prestige Consumer Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00
Prestige Consumer Healthcare	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

Prestige Consumer Healthcare has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Prestige Consumer Healthcare	$1.09B	2.28	$190.30M	$3.57	14.70

Prestige Consumer Healthcare has a net margin of 15.57% compared to Definium Therapeutics' net margin of 0.00%. Prestige Consumer Healthcare's return on equity of 11.39% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Prestige Consumer Healthcare	15.57%	11.39%	5.66%

Definium Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market. Comparatively, Prestige Consumer Healthcare has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

27.9% of Definium Therapeutics shares are held by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by company insiders. Comparatively, 1.5% of Prestige Consumer Healthcare shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Prestige Consumer Healthcare beats Definium Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Prestige Consumer Healthcare News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PBH vs. The Competition

Export

Metric	Prestige Consumer Healthcare	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$2.43B	$12.21B	$7.24B	$24.25B
Dividend Yield	N/A	2.62%	2.54%	3.71%
P/E Ratio	14.70	780.29	271.50	30.00
Price / Sales	2.28	756.07	624.07	20.68
Price / Cash	9.83	95.73	79.29	33.10
Price / Book	1.30	11.93	12.95	7.67
Net Income	$190.30M	$2.81B	$3.46B	$1.07B
7 Day Performance	2.38%	0.52%	-0.11%	-0.32%
1 Month Performance	0.60%	6.37%	8.32%	2.37%
1 Year Performance	-22.95%	6.09%	24.64%	13.30%

Prestige Consumer Healthcare Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PBH Prestige Consumer Healthcare	3.5082 of 5 stars	$52.48 +2.5%	$70.75 +34.8%	-22.1%	$2.43B	$1.09B	14.70	540	Trending News Analyst Revision
CRNX Crinetics Pharmaceuticals	1.6717 of 5 stars	$84.77 +0.0%	$81.00 -4.4%	+176.8%	$8.99B	$42.16M	N/A	210	Positive News
LQDA Liquidia	4.1688 of 5 stars	$74.13 -4.6%	$98.08 +32.3%	+146.5%	$6.66B	$450.91M	54.29	50	Insider Trade
LNTH Lantheus	4.1345 of 5 stars	$100.70 -0.2%	$108.11 +7.4%	+81.6%	$6.58B	$1.54B	24.33	1,193	Positive News
BLTE Belite Bio	3.1161 of 5 stars	$161.88 -0.8%	$205.80 +27.1%	+135.2%	$6.49B	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PBH) was last updated on 8/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prestige Consumer Healthcare (PBH) Competitors

PBH vs. CRNX, LQDA, LNTH, BLTE, and DFTX

How does Prestige Consumer Healthcare compare to Crinetics Pharmaceuticals?

Summary

How does Prestige Consumer Healthcare compare to Liquidia?

Summary

How does Prestige Consumer Healthcare compare to Lantheus?

Summary

How does Prestige Consumer Healthcare compare to Belite Bio?

Summary

How does Prestige Consumer Healthcare compare to Definium Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBH vs. The Competition

Prestige Consumer Healthcare Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prestige Consumer Healthcare (PBH) Competitors

PBH vs. CRNX, LQDA, LNTH, BLTE, and DFTX

How does Prestige Consumer Healthcare compare to Crinetics Pharmaceuticals?

Which has more risk & volatility, CRNX or PBH?

Is CRNX or PBH more profitable?

Do analysts recommend CRNX or PBH?

Do institutionals and insiders have more ownership in CRNX or PBH?

Does the media favor CRNX or PBH?

Which has stronger earnings and valuation, CRNX or PBH?

Summary

How does Prestige Consumer Healthcare compare to Liquidia?

Which has more risk & volatility, LQDA or PBH?

Does the media favor LQDA or PBH?

Do institutionals & insiders hold more shares of LQDA or PBH?

Which has better valuation and earnings, LQDA or PBH?

Is LQDA or PBH more profitable?

Do analysts rate LQDA or PBH?

Summary

How does Prestige Consumer Healthcare compare to Lantheus?

Which has better valuation and earnings, LNTH or PBH?

Do analysts recommend LNTH or PBH?

Is LNTH or PBH more profitable?

Do insiders & institutionals hold more shares of LNTH or PBH?

Which has more risk & volatility, LNTH or PBH?

Does the media favor LNTH or PBH?

Summary

How does Prestige Consumer Healthcare compare to Belite Bio?

Which has better earnings & valuation, BLTE or PBH?

Which has more risk & volatility, BLTE or PBH?

Does the media favor BLTE or PBH?

Do analysts prefer BLTE or PBH?

Do institutionals & insiders have more ownership in BLTE or PBH?

Is BLTE or PBH more profitable?

Summary

How does Prestige Consumer Healthcare compare to Definium Therapeutics?

Does the media favor DFTX or PBH?

Do analysts recommend DFTX or PBH?

Which has higher valuation and earnings, DFTX or PBH?

Is DFTX or PBH more profitable?

Which has more risk & volatility, DFTX or PBH?

Do insiders & institutionals believe in DFTX or PBH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBH vs. The Competition

Prestige Consumer Healthcare Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools